|
EP3409296A1
(en)
|
2005-04-07 |
2018-12-05 |
The Trustees of the University of Pennsylvania |
Method of increasing the function of an aav vector
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
PH12016500162B1
(en)
*
|
2013-07-22 |
2024-02-21 |
Childrens Hospital Philadelphia |
Variant aav and compositions, methods and uses for gene trnsfer to cells, organs, and tissues
|
|
PL3851537T3
(pl)
|
2014-04-25 |
2024-09-16 |
Genethon |
Leczenie hiperbilirubinemii
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
KR20170096998A
(ko)
|
2014-11-05 |
2017-08-25 |
보이저 테라퓨틱스, 인크. |
파킨슨병의 치료를 위한 aadc 폴리뉴클레오티드
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
WO2016077687A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
WO2016077689A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
WO2016094783A1
(en)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
US10081659B2
(en)
|
2015-04-06 |
2018-09-25 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Adeno-associated vectors for enhanced transduction and reduced immunogenicity
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
US11103597B2
(en)
*
|
2015-05-14 |
2021-08-31 |
St. Jude Children's Research Hospital, Inc. |
Nucleic acid molecules containing spacers outside ITR
|
|
CA2990193A1
(en)
*
|
2015-06-23 |
2016-12-29 |
The Children's Hospital Of Philadelphia |
Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
|
|
PT3356390T
(pt)
|
2015-09-28 |
2021-04-21 |
Univ Florida |
Métodos e composições para vetores virais que se evadem a anticorpos
|
|
PE20231949A1
(es)
*
|
2015-10-30 |
2023-12-05 |
Spark Therapeutics Inc |
VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
|
|
WO2017077451A1
(en)
|
2015-11-05 |
2017-05-11 |
Bamboo Therapeutics, Inc. |
Modified friedreich ataxia genes and vectors for gene therapy
|
|
MX2018006682A
(es)
*
|
2015-12-01 |
2018-09-26 |
Spark Therapeutics Inc |
Metodos escalables para producir vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspension libre de suero adecuado para su uso clinico.
|
|
WO2017096164A1
(en)
|
2015-12-02 |
2017-06-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
|
|
US10983110B2
(en)
|
2015-12-02 |
2021-04-20 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
US10406244B2
(en)
|
2015-12-02 |
2019-09-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
AAV vectors with expanded packaging capacity
|
|
US20180363000A1
(en)
*
|
2015-12-14 |
2018-12-20 |
The Trustees Of The University Of Pennsylvania |
Aav-anti pcsk9 antibody constructs and uses thereof
|
|
JP7061067B2
(ja)
|
2015-12-14 |
2022-04-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
クリグラー・ナジャー症候群の処置のための組成物
|
|
US10179176B2
(en)
|
2016-02-16 |
2019-01-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
|
|
CA3019126A1
(en)
*
|
2016-03-30 |
2017-10-05 |
Spark Therapeutics, Inc. |
Cell line for recombinant protein and/or viral vector production
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
BR112018073472A2
(pt)
|
2016-05-18 |
2019-08-27 |
Voyager Therapeutics Inc |
composições e métodos de tratamento da doença de huntington
|
|
CA3024448C
(en)
|
2016-05-18 |
2025-09-09 |
Voyager Therapeutics, Inc. |
MODULATING POLYNUCLEOTIDES
|
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
EP3491008A2
(en)
|
2016-07-26 |
2019-06-05 |
BioMarin Pharmaceutical Inc. |
Novel adeno-associated virus capsid proteins
|
|
JP2019531787A
(ja)
|
2016-08-30 |
2019-11-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
US11339406B2
(en)
|
2016-09-12 |
2022-05-24 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293260A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293203A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3534892A4
(en)
*
|
2016-11-04 |
2020-05-27 |
The Children's Hospital of Philadelphia |
GENE TRANSFER COMPOSITIONS, METHODS AND USE FOR TREATING NEURODEGENERATIVE DISEASES
|
|
US20230190958A1
(en)
|
2017-01-13 |
2023-06-22 |
Jichi Medical University |
AAV Vector for Disrupting Coagulation Factor-Related Gene on Liver Genome
|
|
CN110914419A
(zh)
|
2017-03-10 |
2020-03-24 |
吉尼松公司 |
糖原贮积病iii的治疗
|
|
US10550405B2
(en)
|
2017-03-15 |
2020-02-04 |
The University Of North Carolina At Chapel Hill |
Rational polyploid adeno-associated virus vectors and methods of making and using the same
|
|
CN110770346B
(zh)
*
|
2017-03-15 |
2024-01-12 |
北卡罗来纳-查佩尔山大学 |
多倍体腺相关病毒载体及其制备和使用方法
|
|
SG11201909868YA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
WO2018204786A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
US20200172927A1
(en)
*
|
2017-05-15 |
2020-06-04 |
The Trustees Of Columbia University In The City Of New York |
Reprogramming metabolism by inhibiting vhl for treatment of neurodegeneration
|
|
CA3066358A1
(en)
|
2017-06-07 |
2018-12-13 |
Spark Therapeutics, Inc. |
Enhancing agents for improved cell transfection and/or raav vector production
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CA3069880A1
(en)
*
|
2017-07-17 |
2019-01-24 |
Spark Therapeutics, Inc. |
Apheresis methods and uses
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
|
CN111163811A
(zh)
*
|
2017-08-25 |
2020-05-15 |
奥维德医疗公司 |
重组腺相关载体
|
|
CA3075656A1
(en)
|
2017-09-29 |
2019-04-04 |
Voyager Therapeutics, Inc. |
Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
|
|
WO2019079240A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
EP4454654A3
(en)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
KR102892243B1
(ko)
|
2018-01-17 |
2025-11-27 |
아드레나스 테라퓨틱스, 인코포레이티드 |
21-하이드록실라제 결핍을 위한 아데노-관련 바이러스 유전자 요법
|
|
WO2019152843A1
(en)
|
2018-02-01 |
2019-08-08 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
CN111902539B
(zh)
*
|
2018-02-07 |
2025-05-16 |
吉尼松公司 |
杂合调控元件
|
|
US11306329B2
(en)
|
2018-02-19 |
2022-04-19 |
City Of Hope |
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
|
|
AU2019227726B2
(en)
*
|
2018-02-27 |
2025-09-04 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (AAV) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
|
EP3765624A4
(en)
*
|
2018-03-16 |
2022-05-25 |
Research Institute at Nationwide Children's Hospital |
Increasing tissue specific gene delivery by capsid modification
|
|
JP7378417B2
(ja)
|
2018-03-30 |
2023-11-13 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
増強されたヒト膵臓トロピズムを有する新規な組換えアデノ随伴ウイルスキャプシド
|
|
JP7425738B2
(ja)
|
2018-04-03 |
2024-01-31 |
ギンコ バイオワークス インコーポレイテッド |
眼組織を標的とするウイルスベクター
|
|
SG11202009452WA
(en)
|
2018-04-03 |
2020-10-29 |
Stridebio Inc |
Antibody-evading virus vectors
|
|
JP2021519581A
(ja)
|
2018-04-03 |
2021-08-12 |
ストライドバイオ，インコーポレイテッド |
抗体を回避するウイルスベクター
|
|
CA3093347A1
(en)
*
|
2018-04-05 |
2019-10-10 |
Genethon |
Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism
|
|
US12054724B2
(en)
|
2018-04-10 |
2024-08-06 |
President And Fellows Of Harvard College |
AAV vectors encoding clarin-1 or GJB2 and uses thereof
|
|
WO2019210267A2
(en)
*
|
2018-04-27 |
2019-10-31 |
Spark Therapeutics, Inc. |
Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
|
|
WO2019212922A1
(en)
|
2018-04-29 |
2019-11-07 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
US12365865B2
(en)
|
2018-04-29 |
2025-07-22 |
Regenxbio Inc. |
Scalable clarification process for recombinant AAV production
|
|
NZ759802A
(en)
*
|
2018-05-07 |
2025-08-29 |
Univ North Carolina Chapel Hill |
Rational polyploid adeno-associated virus vectors and methods of making and using the same
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
JP2021523914A
(ja)
|
2018-05-15 |
2021-09-09 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
パーキンソン病を治療するための組成物および方法
|
|
US12070702B2
(en)
|
2018-06-14 |
2024-08-27 |
Regenxbio Inc. |
Anion exchange chromatography for recombinant AAV production
|
|
DK3833746T5
(da)
|
2018-08-08 |
2024-08-19 |
Genethon |
Mini-gde til behandlingen af glykogenlagringssygdom iii
|
|
AU2019319976B2
(en)
|
2018-08-10 |
2025-08-14 |
Regenxbio Inc. |
Scalable method for recombinant AAV production
|
|
US10842885B2
(en)
|
2018-08-20 |
2020-11-24 |
Ucl Business Ltd |
Factor IX encoding nucleotides
|
|
GB201813528D0
(en)
|
2018-08-20 |
2018-10-03 |
Ucl Business Plc |
Factor IX encoding nucleotides
|
|
JP7528066B2
(ja)
|
2018-09-28 |
2024-08-05 |
ボイジャー セラピューティクス インコーポレイテッド |
操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
|
|
WO2020081415A1
(en)
|
2018-10-15 |
2020-04-23 |
Regenxbio Inc. |
Method for measuring the infectivity of replication defective viral vectors and viruses
|
|
US12383587B2
(en)
|
2018-10-25 |
2025-08-12 |
Takeda Pharmaceutical Company Limited |
AAV triple-plasmid system
|
|
EP3880830A4
(en)
*
|
2018-11-16 |
2022-08-24 |
Asklepios Biopharmaceutical, Inc. |
VECTORS COMPRISING NUCLEIC ACID ENCODING LYSOSOMAL ENZYMES FUSED TO A LYSOSOMAL TARGETING SEQUENCE
|
|
AU2020241888A1
(en)
|
2019-03-21 |
2021-09-30 |
Ginkgo Bioworks, Inc. |
Recombinant adeno-associated virus vectors
|
|
BR112021019436A2
(pt)
*
|
2019-03-28 |
2021-12-07 |
Harvard College |
Vetores de vírus adeno-associados (aav) modificados para expressão transgênica
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
HUE064411T2
(hu)
|
2019-04-11 |
2024-03-28 |
Regenxbio Inc |
Méretkizárásos kromatográfiás módszerek rekombináns adeno-asszociált víruskészítmények jellemzésére
|
|
CN113993552A
(zh)
|
2019-04-19 |
2022-01-28 |
再生生物股份有限公司 |
腺相关病毒载体制剂和方法
|
|
CN113692411A
(zh)
|
2019-04-19 |
2021-11-23 |
吉尼松公司 |
成纤维细胞生长因子23相关的低磷酸盐血症的基因治疗
|
|
SG11202111414RA
(en)
|
2019-04-24 |
2021-11-29 |
Regenxbio Inc |
Fully-human post-translationally modified antibody therapeutics
|
|
WO2020223236A1
(en)
*
|
2019-04-29 |
2020-11-05 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
EP3967706A4
(en)
*
|
2019-05-08 |
2022-12-28 |
Center For Excellence In Brain Science And Intelligence Technology, Chinese Academy Of Sciences |
AAV MUTANT FOR EFFICIENT INFECTION OF SUPPORT CELLS
|
|
CN110205297A
(zh)
*
|
2019-05-15 |
2019-09-06 |
华北理工大学 |
一种重组脂肪干细胞及其重组方法
|
|
CA3144864A1
(en)
|
2019-06-27 |
2020-12-30 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
EP3996696A1
(en)
|
2019-07-09 |
2022-05-18 |
Genethon |
Treatment of glycogen storage disease (gsd)
|
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
WO2021009805A1
(ja)
|
2019-07-12 |
2021-01-21 |
株式会社遺伝子治療研究所 |
ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
|
|
WO2021021661A1
(en)
|
2019-07-26 |
2021-02-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
RU2751592C2
(ru)
*
|
2019-08-22 |
2021-07-15 |
Общество С Ограниченной Ответственностью "Анабион" |
Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
|
|
US20220298514A1
(en)
*
|
2019-09-11 |
2022-09-22 |
Aav Gene Therapeutics, Inc. |
Aav-zyme and use for infusion replacement therapy
|
|
KR20220083714A
(ko)
|
2019-10-17 |
2022-06-20 |
스트라이드바이오 인코포레이티드 |
니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
|
|
WO2021078834A1
(en)
|
2019-10-22 |
2021-04-29 |
Genethon |
Chimeric acid-alpha glucosidase polypeptides and uses thereof
|
|
US20230033268A1
(en)
|
2019-10-22 |
2023-02-02 |
Genethon |
Chimeric polypeptides and uses thereof
|
|
AU2020384294A1
(en)
*
|
2019-11-14 |
2022-06-02 |
Biomarin Pharmaceutical Inc. |
Treatment of hereditary angioedema with liver-specific gene therapy vectors
|
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
|
JP2023503637A
(ja)
|
2019-11-28 |
2023-01-31 |
リジェネックスバイオ インコーポレイテッド |
マイクロジストロフィン遺伝子治療コンストラクト及びその使用
|
|
KR20220118421A
(ko)
|
2019-12-18 |
2022-08-25 |
제네똥 |
식물 모상근으로부터 재조합 바이러스 벡터의 제조
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
JP2023512043A
(ja)
|
2020-01-29 |
2023-03-23 |
レジェンクスバイオ インコーポレーテッド |
ムコ多糖症ｉｖａの治療
|
|
EP3892720A1
(en)
|
2020-04-06 |
2021-10-13 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Presenting cell and use thereof in cell therapy
|
|
WO2021229255A1
(en)
|
2020-05-14 |
2021-11-18 |
Genethon |
Tools and method for preventing a a¥ neutralization by antibodies
|
|
EP3913060A1
(en)
|
2020-05-22 |
2021-11-24 |
Genethon |
Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
JP2023532923A
(ja)
*
|
2020-06-30 |
2023-08-01 |
チルドレンズ ナショナル メディカル センター |
骨格筋線維の修復を改善するためのリコンビナントヒト酸性スフィンゴミエリナーゼの使用
|
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
|
AR123288A1
(es)
|
2020-08-19 |
2022-11-16 |
Stridebio Inc |
Vectores de virus adenoasociados para el tratamiento del síndrome de rett
|
|
EP4200410A1
(en)
|
2020-08-24 |
2023-06-28 |
Genethon |
C-terminal truncated gde for the treatment of glycogen storage disease iii
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
EP4213890A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized lanadelumab and administration thereof
|
|
JP2023545722A
(ja)
|
2020-10-07 |
2023-10-31 |
リジェネックスバイオ インコーポレイテッド |
遺伝子治療剤の眼送達のためのアデノ随伴ウイルス
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
JP2023548746A
(ja)
|
2020-10-13 |
2023-11-21 |
クリヤ セラピューティクス インコーポレイテッド |
サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
|
|
IL302045A
(en)
|
2020-10-15 |
2023-06-01 |
Hoffmann La Roche |
Nucleic acid constructs for simultaneous gene activation
|
|
ES3035361T3
(en)
|
2020-10-15 |
2025-09-02 |
Hoffmann La Roche |
Nucleic acid constructs for va rna transcription
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
AU2021371307A1
(en)
|
2020-10-28 |
2023-06-01 |
Regenxbio, Inc. |
VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
|
|
CN116457373A
(zh)
|
2020-10-29 |
2023-07-18 |
再生生物股份有限公司 |
用于眼部适应症的载体化TNF-α拮抗剂
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
CA3200401A1
(en)
|
2020-11-03 |
2022-05-12 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
CA3199661A1
(en)
|
2020-12-09 |
2022-06-16 |
Mario Amendola |
Lysosomal acid lipase variants and uses thereof
|
|
WO2022130172A1
(en)
|
2020-12-15 |
2022-06-23 |
Pfizer Inc. |
Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
|
|
IL303614A
(en)
|
2020-12-16 |
2023-08-01 |
Regenxbio Inc |
Method of producing a recombinant adeno-associated virus particle
|
|
IL303959A
(en)
|
2020-12-23 |
2023-08-01 |
Pfizer |
Methods for purification of aav vectors by affinity chromatography
|
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
|
EP4281568A1
(en)
|
2021-01-21 |
2023-11-29 |
RegenxBio Inc. |
Improved production of recombinant polypeptides and viruses
|
|
US20240191213A1
(en)
|
2021-03-19 |
2024-06-13 |
Adrenas Therapeutics, Inc. |
Gene therapies for 21-hydroxylase deficiency
|
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
CA3216491A1
(en)
*
|
2021-04-16 |
2022-10-20 |
Asklepios Biopharmaceutical, Inc. |
Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
|
|
JP2024515902A
(ja)
|
2021-04-26 |
2024-04-10 |
アレクシオン ファーマ インターナショナル オペレーションズ リミテッド |
組織向性が改善されたアデノ随伴ウイルスベクターカプシド
|
|
TW202309293A
(zh)
|
2021-04-26 |
2023-03-01 |
美商銳進科斯生物股份有限公司 |
用於治療肌縮蛋白症(dystrophinopathy)之微小肌縮蛋白基因療法給藥
|
|
US20240218397A1
(en)
|
2021-05-04 |
2024-07-04 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
|
EP4337267A1
(en)
|
2021-05-11 |
2024-03-20 |
RegenxBio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
MX2023015329A
(es)
|
2021-06-22 |
2024-01-23 |
Pfizer |
Produccion de vector de virus adeno-asociado en celulas de insecto.
|
|
EP4373947A1
(en)
|
2021-07-19 |
2024-05-29 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
|
AR126840A1
(es)
*
|
2021-08-20 |
2023-11-22 |
Llc «Anabion» |
Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta
|
|
AR126839A1
(es)
*
|
2021-08-20 |
2023-11-22 |
Llc «Anabion» |
Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
US20250001006A1
(en)
|
2021-10-07 |
2025-01-02 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
EP4413019A2
(en)
|
2021-10-07 |
2024-08-14 |
RegenxBio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
WO2023060264A1
(en)
|
2021-10-08 |
2023-04-13 |
Dyno Therapeutics, Inc. |
Capsid variants and methods of using the same
|
|
WO2023069987A1
(en)
|
2021-10-20 |
2023-04-27 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss cross reference to related application
|
|
EP4423285A1
(en)
|
2021-10-28 |
2024-09-04 |
RegenxBio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
WO2023081633A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
US20230227779A1
(en)
|
2022-01-19 |
2023-07-20 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment
|
|
JP2025504478A
(ja)
|
2022-01-21 |
2025-02-12 |
アストラゼネカ アイルランド リミテッド |
ゴーシェ病の遺伝子療法
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
EP4493226A1
(en)
|
2022-03-13 |
2025-01-22 |
RegenxBio Inc. |
Modified muscle-specific promoters
|
|
US20250213727A1
(en)
|
2022-03-25 |
2025-07-03 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
EP4508241A1
(en)
|
2022-04-13 |
2025-02-19 |
F. Hoffmann-La Roche AG |
Method for determining aav genomes
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
US20250249127A1
(en)
|
2022-04-14 |
2025-08-07 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
EP4518973A1
(en)
|
2022-05-03 |
2025-03-12 |
RegenxBio Inc. |
Vectorized anti-tnf-alpha inhibitors for ocular indications
|
|
WO2023215806A2
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
JP2025517987A
(ja)
|
2022-05-23 |
2025-06-12 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ａａｖ粒子血清型およびａａｖ粒子負荷状態の識別のためのラマンベースの方法
|
|
CN119301260A
(zh)
|
2022-06-03 |
2025-01-10 |
豪夫迈·罗氏有限公司 |
用于生产重组aav颗粒的方法
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
CA3252764A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
GDE truncated at the N-terminal level for the treatment of type III glycogen storage disease
|
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
|
CA3261054A1
(en)
|
2022-07-14 |
2024-01-18 |
F. Hoffmann-La Roche Ag |
PROCESS FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLES
|
|
EP4558149A1
(en)
|
2022-07-21 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
IL317385A
(en)
|
2022-08-15 |
2025-02-01 |
Hoffmann La Roche |
Preventing or reducing side effects associated with recombinant viral vectors
|
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
JP2025527658A
(ja)
|
2022-08-24 |
2025-08-22 |
リジェネックスバイオ インコーポレイテッド |
組換えアデノ随伴ウイルス及びその使用
|
|
KR20250067819A
(ko)
|
2022-09-12 |
2025-05-15 |
에프. 호프만-라 로슈 아게 |
핵산 포함 및 핵산 비포함 aav 입자를 분리하는 방법
|
|
JP2025534666A
(ja)
|
2022-10-11 |
2025-10-17 |
リジェネックスバイオ インコーポレイテッド |
操作された核酸調節エレメントならびにその使用方法
|
|
CN120752339A
(zh)
|
2023-01-06 |
2025-10-03 |
国家医疗保健研究所 |
静脉内施用用于治疗疼痛的反义寡核苷酸
|
|
WO2024163747A2
(en)
|
2023-02-02 |
2024-08-08 |
University Of Rochester |
Competitive replacement of glial cells
|
|
AU2024216670A1
(en)
|
2023-02-07 |
2025-07-31 |
F. Hoffmann-La Roche Ag |
Method for the detection of anti-aav particle antibodies
|
|
WO2024192281A2
(en)
|
2023-03-15 |
2024-09-19 |
Regenxbio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
KR20250162543A
(ko)
|
2023-03-21 |
2025-11-18 |
에프. 호프만-라 로슈 아게 |
재조합 aav 입자 제제 생산 방법
|
|
WO2024211780A1
(en)
|
2023-04-07 |
2024-10-10 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
CN120936723A
(zh)
|
2023-04-13 |
2025-11-11 |
豪夫迈·罗氏有限公司 |
改进的重组多腺苷酸化信号序列及其用途
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
WO2024233099A1
(en)
*
|
2023-05-05 |
2024-11-14 |
Regeneron Pharmaceuticals, Inc. |
Labeling and anti-drug antibody assays for aav vectors
|
|
WO2024233529A2
(en)
|
2023-05-07 |
2024-11-14 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2024238867A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2025003477A1
(en)
|
2023-06-29 |
2025-01-02 |
Genethon |
N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease iii
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
WO2025082618A1
(en)
|
2023-10-20 |
2025-04-24 |
Fuse Vectors Aps |
In vitro parvovirus capsid manufacturing
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025168663A1
(en)
|
2024-02-09 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant adeno-associated viral particles
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
WO2025217230A1
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
WO2025250454A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
|
|
WO2025252480A1
(en)
|
2024-06-07 |
2025-12-11 |
F. Hoffmann-La Roche Ag |
Method for purifying plasmid dna
|